SMi proudly present their 2nd Annual conference on Immunogenicity taking place on 29th & 30th June 2015 in London.
This year's conference will explore the latest updates on the prediction and reduction of immunogenicity, clinical results and interpretations and optimising bioassays. Through a series of interactive presentations, workshop led by selected case studies from leading drug development teams, bioanalytical experts, and academics the programme aims to provide insight on developments necessary to deliver safe, efficacious large molecule drugs to improve the lives of patients.
Reasons why you should attend:
• Gain an understanding of immunogenicity and challenges in biologics development
• Explore tolerance induction techniques in detail
• Discover the latest in pre-clinical models
• Learn more about neutralising antibody assay best practice
• Receive updates on the ABIRISK project
Keynote speakers include:
• Annie De Groot, CEO and CSO, EpiVax, Inc.
• Sandra Garcês, Rheumatologist Consultant and Researcher, Garcia de Orta’s Hospital
• David Wraith, Chief Scientific Officer and Founder, Apitope International NV
• Margareta Wikén, Bioanalytical Manager, Swedish Orphan Biovitrum
• Morten Nielsen, Associate Professor, The Technical University of Denmark
• Gerhard Niederfellner, Head of Tumour Cell Biology, Pharma Research & Early Development, Roche Innovation Center Penzberg
• Chloé Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University of Brussels
In addition, don’t miss the half day post-conference workshop taking place on the 1st July:
• Tools for early immunogenicity risk assessment and reduction
Workshop Leaders: Sofie Pattijn, CTO, ImmunXperts SA and Morten Nielsen, Associate Professor, Center for Biological Sequence Analysis, Technical University of Denmark
HOW TO REGISTER
Register online at www.immuno.co.uk/Å·ÃÀAV
Contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk
This year's conference will explore the latest updates on the prediction and reduction of immunogenicity, clinical results and interpretations and optimising bioassays. Through a series of interactive presentations, workshop led by selected case studies from leading drug development teams, bioanalytical experts, and academics the programme aims to provide insight on developments necessary to deliver safe, efficacious large molecule drugs to improve the lives of patients.
Reasons why you should attend:
• Gain an understanding of immunogenicity and challenges in biologics development
• Explore tolerance induction techniques in detail
• Discover the latest in pre-clinical models
• Learn more about neutralising antibody assay best practice
• Receive updates on the ABIRISK project
Keynote speakers include:
• Annie De Groot, CEO and CSO, EpiVax, Inc.
• Sandra Garcês, Rheumatologist Consultant and Researcher, Garcia de Orta’s Hospital
• David Wraith, Chief Scientific Officer and Founder, Apitope International NV
• Margareta Wikén, Bioanalytical Manager, Swedish Orphan Biovitrum
• Morten Nielsen, Associate Professor, The Technical University of Denmark
• Gerhard Niederfellner, Head of Tumour Cell Biology, Pharma Research & Early Development, Roche Innovation Center Penzberg
• Chloé Ackaert, Postdoctoral Researcher, Cellular and Molecular Immunology, Free University of Brussels
In addition, don’t miss the half day post-conference workshop taking place on the 1st July:
• Tools for early immunogenicity risk assessment and reduction
Workshop Leaders: Sofie Pattijn, CTO, ImmunXperts SA and Morten Nielsen, Associate Professor, Center for Biological Sequence Analysis, Technical University of Denmark
HOW TO REGISTER
Register online at www.immuno.co.uk/Å·ÃÀAV
Contact Fateja Begum on +44 (0)20 7827 6184 or email fbegum@smi-online.co.uk
